$STEK
Stemtech Corp

2024 Q3 Form 10-K Financial Statement

#000168316824004736 Filed on July 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q4 2023
Revenue $1.362M $4.922M
YoY Change 26.13% 7.94%
Cost Of Revenue $219.8K $1.002M
YoY Change -32.92% -13.95%
Gross Profit $1.142M $3.920M
YoY Change 51.85% 15.45%
Gross Profit Margin 83.86% 79.65%
Selling, General & Admin $2.190M $6.944M
YoY Change 143.77% -5.8%
% of Gross Profit 191.74% 177.14%
Research & Development $0.00 $13.80K
YoY Change
% of Gross Profit 0.0% 0.35%
Depreciation & Amortization $155.8K $587.8K
YoY Change 32.87% 31.38%
% of Gross Profit 13.64% 15.0%
Operating Expenses $2.569M $8.144M
YoY Change 116.92% -3.26%
Operating Profit -$1.427M -$4.225M
YoY Change 230.13% -15.9%
Interest Expense -$456.2K -$2.038M
YoY Change 123.42% -72.16%
% of Operating Profit
Other Income/Expense, Net $19.11K -$1.207M
YoY Change 3085.0% -65.64%
Pretax Income -$1.864M -$5.432M
YoY Change 317.83% -36.37%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.865M -$5.430M
YoY Change 259.4% -36.45%
Net Earnings / Revenue -136.94% -110.34%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.02 -$0.07
COMMON SHARES
Basic Shares Outstanding 116.8M shares 104.5M shares 83.47M shares
Diluted Shares Outstanding 83.47M shares

Balance Sheet

Concept 2024 Q3 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.2K $114.2K
YoY Change -13.83% -13.83%
Cash & Equivalents $114.2K
Short-Term Investments
Other Short-Term Assets $176.7K $176.7K
YoY Change -38.43% -38.43%
Inventory $48.33K $48.33K
Prepaid Expenses
Receivables $61.49K $61.49K
Other Receivables $0.00 $0.00
Total Short-Term Assets $400.7K $400.7K
YoY Change -34.56% -34.56%
LONG-TERM ASSETS
Property, Plant & Equipment $10.06K $80.88K
YoY Change -63.16% -52.45%
Goodwill $467.4K
YoY Change 0.0%
Intangibles $2.711M
YoY Change -9.47%
Long-Term Investments $23.71K $23.71K
YoY Change 2.77% 2.77%
Other Assets
YoY Change
Total Long-Term Assets $3.283M $3.283M
YoY Change -10.18% -10.18%
TOTAL ASSETS
Total Short-Term Assets $400.7K $400.7K
Total Long-Term Assets $3.283M $3.283M
Total Assets $3.683M $3.683M
YoY Change -13.68% -13.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.709M $2.709M
YoY Change -20.25% -20.25%
Accrued Expenses $66.87K $66.87K
YoY Change -43.84% -43.84%
Deferred Revenue
YoY Change
Short-Term Debt $3.630M $3.630M
YoY Change 217.5% 217.5%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.462M $6.462M
YoY Change -12.86% -12.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.462M $6.462M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.462M $5.723M
YoY Change -13.13% -14.6%
SHAREHOLDERS EQUITY
Retained Earnings -$27.06M
YoY Change 25.1%
Common Stock $105.0K
YoY Change -99.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.039M -$2.039M
YoY Change
Total Liabilities & Shareholders Equity $3.683M $3.683M
YoY Change -13.68% -13.68%

Cashflow Statement

Concept 2024 Q3 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.865M -$5.430M
YoY Change 259.4% -36.45%
Depreciation, Depletion And Amortization $155.8K $587.8K
YoY Change 32.87% 31.38%
Cash From Operating Activities -$1.132M -$2.036M
YoY Change 370.1% 67.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 270.8K $1.579M
YoY Change -253.9% 366.27%
NET CHANGE
Cash From Operating Activities -1.132M -$2.036M
Cash From Investing Activities
Cash From Financing Activities 270.8K $1.579M
Net Change In Cash -861.2K -$18.32K
YoY Change 106.63% -97.37%
FREE CASH FLOW
Cash From Operating Activities -$1.132M -$2.036M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001511820
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 GNTW Settlement Of Accrued Liabilities For Common Stock
SettlementOfAccruedLiabilitiesForCommonStock
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Naples
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34103
CY2023 dei City Area Code
CityAreaCode
954
CY2023 dei Local Phone Number
LocalPhoneNumber
715-6000
CY2023 dei Security12g Title
Security12gTitle
Common Shares - $0.001 par value
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
1683169 usd
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
116769707 shares
CY2023 dei Auditor Firm
AuditorFirmId
76
CY2023 dei Auditor Name
AuditorName
Turner, Stone & Company, LLP
CY2023 dei Auditor Location
AuditorLocation
Dallas, Texas
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114166 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132487 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
61494 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
34767 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
48325 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
158053 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
176725 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
287063 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
400710 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
612370 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10056 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27296 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2710568 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2994000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
23708 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
23065 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70820 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142801 usd
CY2023Q4 us-gaap Goodwill
Goodwill
467409 usd
CY2022Q4 us-gaap Goodwill
Goodwill
467409 usd
CY2023Q4 us-gaap Assets
Assets
3683271 usd
CY2022Q4 us-gaap Assets
Assets
4266941 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2708906 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3396543 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1889321 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
446246 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1596960 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
482885 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66866 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119065 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
56039 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
39170 usd
CY2023Q4 GNTW Factoring Liability
FactoringLiability
143944 usd
CY2022Q4 GNTW Factoring Liability
FactoringLiability
214249 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2717633 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6462036 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7415791 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23068 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6462036 usd
CY2022Q4 us-gaap Liabilities
Liabilities
7438859 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104988853 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104988853 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53442147 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53442147 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
104989 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
53442 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24726722 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19391400 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
190503 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-247760 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27061486 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21631241 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2039272 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2434159 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-739493 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-737759 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2778765 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3171918 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3683271 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4266941 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4921531 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4559399 usd
CY2023 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
731339 usd
CY2022 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
1100903 usd
CY2023 us-gaap Cost Depreciation Amortization And Depletion
CostDepreciationAmortizationAndDepletion
270301 usd
CY2022 us-gaap Cost Depreciation Amortization And Depletion
CostDepreciationAmortizationAndDepletion
63115 usd
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1001640 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1164018 usd
CY2023 us-gaap Gross Profit
GrossProfit
3919891 usd
CY2022 us-gaap Gross Profit
GrossProfit
3395381 usd
CY2023 GNTW Commission Expenses
CommissionExpenses
1187025 usd
CY2022 GNTW Commission Expenses
CommissionExpenses
1047400 usd
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
504075 usd
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
533397 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13800 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
8144437 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
8418761 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-4224546 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-5023380 usd
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1488686 usd
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3223271 usd
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
4893033 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
4097843 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16484 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7928 usd
CY2023 GNTW Gain On Settlement Of Derivative Liabilities
GainOnSettlementOfDerivativeLiabilities
1366298 usd
CY2022 GNTW Gain On Settlement Of Derivative Liabilities
GainOnSettlementOfDerivativeLiabilities
0 usd
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
814132 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3799356 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1207433 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3513830 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5431979 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8537210 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95618 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-5431979 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-8632828 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1734 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87905 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5430245 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8544923 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83469544 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46014138 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83469544 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46014138 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5430245 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8544923 usd
CY2023 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-438263 usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-182495 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4991982 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8362428 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4005446 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
439053 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3557132 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100002 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
828000 usd
CY2022 GNTW Stock Issued For Loan Extensions
StockIssuedForLoanExtensions
4159674 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200000 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
182495 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87905 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8544923 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3171918 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3171918 usd
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
439054 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
434025 usd
CY2023 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
2403453 usd
CY2023 GNTW Settlement Of Accrued Liabilities For Common Stock
SettlementOfAccruedLiabilitiesForCommonStock
807076 usd
CY2023 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
271920 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1011451 usd
CY2023 GNTW Stock Issued For Loan Extensions
StockIssuedForLoanExtensions
19890 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
438263 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1734 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-5430245 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2778765 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-5431979 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-8632828 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
587797 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
447386 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
71981 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
439054 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3996187 usd
CY2023 GNTW Noncash Interest Expense From Issuance On Debt Derivative
NoncashInterestExpenseFromIssuanceOnDebtDerivative
1623579 usd
CY2022 GNTW Noncash Interest Expense From Issuance On Debt Derivative
NoncashInterestExpenseFromIssuanceOnDebtDerivative
0 usd
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2797403 usd
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2428539 usd
CY2023 GNTW Amortization Due To Conversionredemptions
AmortizationDueToConversionredemptions
0 usd
CY2022 GNTW Amortization Due To Conversionredemptions
AmortizationDueToConversionredemptions
1457542 usd
CY2023 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1488686 usd
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-3223271 usd
CY2023 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
1366298 usd
CY2022 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-0 usd
CY2023 GNTW Stock Issued For Loan Extension
StockIssuedForLoanExtension
19890 usd
CY2022 GNTW Stock Issued For Loan Extension
StockIssuedForLoanExtension
0 usd
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
434025 usd
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
814132 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3799356 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26727 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24047 usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-109728 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-278352 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110338 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-37645 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
957056 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-683058 usd
CY2023 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
643 usd
CY2022 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-15627 usd
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-75267 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1378 usd
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16869 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
39170 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2036012 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1216948 usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2236000 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
611266 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
466872 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
586783 usd
CY2023 GNTW Net Repayments Proceeds From Factoring Arrangement
NetRepaymentsProceedsFromFactoringArrangement
-189700 usd
CY2022 GNTW Net Repayments Proceeds From Factoring Arrangement
NetRepaymentsProceedsFromFactoringArrangement
214249 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100002 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1579428 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
338734 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
438263 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182495 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18321 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-695719 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132487 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
828206 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114166 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132487 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
6821 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
36205 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023 GNTW Stock Issued For Lfr Acquisition
StockIssuedForLfrAcquisition
271920 usd
CY2022 GNTW Stock Issued For Lfr Acquisition
StockIssuedForLfrAcquisition
0 usd
CY2023 GNTW Issuance Of Common Stock For Conversion Of Debt
IssuanceOfCommonStockForConversionOfDebt
2403453 usd
CY2022 GNTW Issuance Of Common Stock For Conversion Of Debt
IssuanceOfCommonStockForConversionOfDebt
828000 usd
CY2023 us-gaap Stock Issued1
StockIssued1
0 usd
CY2022 us-gaap Stock Issued1
StockIssued1
200000 usd
CY2023 GNTW Settlement Of Accrued Liabilities For Common Stock
SettlementOfAccruedLiabilitiesForCommonStock
807076 usd
CY2023 GNTW Reclassification Of Derivative Liabilities To Apic
ReclassificationOfDerivativeLiabilitiesToApic
1011451 usd
CY2022 GNTW Reclassification Of Derivative Liabilities To Apic
ReclassificationOfDerivativeLiabilitiesToApic
0 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80D_eus-gaap--NatureOfOperations_zZwb8WaHmb57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 –<span id="xdx_829_zyLMMkj2lRIi"> Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stemtech Corporation and its Subsidiaries (collectively, the “<b>Company</b>”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14, 2022, FINRA gave final approval for said name change, as evidenced by the 8-K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Company’s subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™ and OraStem® (Oral Health Care), and Cellect One™ Rapid Renew Stem Cell Peptide Night Cream.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, Stemtech Corporation (“<b>Stemtech</b>”), a Delaware corporation, entered into a Merger Agreement (the “<b>Merger Agreement</b>”) with Globe Net Wireless Corp. (“<b>Globe Net</b>” or “<b>GNTW</b>”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, <i>Business Combinations</i>. Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end from a fiscal year end of August 31 to a calendar year end of December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>  </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Stemtech (Parent) and its (12) subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Canada, Inc. (“Canada”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia Holdings”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Sdn. Bhd. (“Malaysia”) – 70%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Taiwan Holding, Inc. (“Taiwan”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td>8.</td> <td>Stemtech Taiwan Branch – 100%</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tecrecel S.A. (“Ecuador”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Food &amp; Health Tech Foodhealth SA (“Ecuador FHTFH”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life Factor Research (“LFR”) – 100%</span></td></tr> <tr style="vertical-align: top"> <td>12.</td> <td>Stemtech IP Holdings, LLC – 100%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q4 GNTW Working Capital
WorkingCapital
-6100000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zxYuDQY6cYQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_864_zuXTy0uiOofe">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zQ1BU8jTbead" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to prior year data to conform to the current year’s presentation. These reclassifications had no impact on reported income or losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15198206 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3010875 shares
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
48325 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
103297 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0 usd
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
54756 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
48325 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
158053 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-2488757 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1918200 usd
CY2023 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
2710568 usd
CY2022 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
2994000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
376287 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
167493 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
167493 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
167493 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
167493 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1664309 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2710568 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
73083 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
85629 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
69330 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
69330 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2464 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66866 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
3486281 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
929131 usd
CY2023Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.13 pure
CY2021Q4 GNTW Derivative Liabilities1
DerivativeLiabilities1
4224585 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
5366289 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
-10096512 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
3223271 usd
CY2022Q4 GNTW Derivative Liabilities1
DerivativeLiabilities1
2717633 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
2626283 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
-3855230 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
-1488686 usd
CY2023Q4 GNTW Derivative Liabilities1
DerivativeLiabilities1
0 usd
CY2022 GNTW Proceeds From Factoring Liability
ProceedsFromFactoringLiability
528984 usd
CY2023 GNTW Proceeds From Factoring Liability
ProceedsFromFactoringLiability
382286 usd
CY2023 GNTW Cash Received For Future Receivables
CashReceivedForFutureReceivables
317111 usd
CY2023Q4 GNTW Factoring Liability Gross
FactoringLiabilityGross
156194 usd
CY2022Q4 GNTW Factoring Liability Gross
FactoringLiabilityGross
292636 usd
CY2023Q4 GNTW Factoring Liability Discount
FactoringLiabilityDiscount
12250 usd
CY2022Q4 GNTW Factoring Liability Discount
FactoringLiabilityDiscount
78387 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q4 GNTW Accounts Payable Related Parties
AccountsPayableRelatedParties
179509 usd
CY2023 us-gaap Revenues
Revenues
4921531 usd
CY2022 us-gaap Revenues
Revenues
4559399 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
1001640 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
1164018 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
8144437 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
8418761 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-4224546 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-5023380 usd
CY2023Q4 us-gaap Assets
Assets
3683271 usd
CY2022Q4 us-gaap Assets
Assets
4266941 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5431979 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8537210 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5431979 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8537210 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1140716 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1792814 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
672813 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2697747 usd
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
79780 usd
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
110120 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
435797 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-495637 usd
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-47674 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-423798 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95618 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6385854 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6132841 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2098976 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1664597 usd
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-70768 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-83111 usd
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1986 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1986 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-27130 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-209 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8384945 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7712132 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8384945 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7712132 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
24800000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
21200000 usd
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-004736-index-headers.html Edgar Link pending
0001683168-24-004736-index.html Edgar Link pending
0001683168-24-004736.txt Edgar Link pending
0001683168-24-004736-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gntw-20231231.xsd Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stemtech_ex1001.htm Edgar Link pending
stemtech_ex1002.htm Edgar Link pending
stemtech_ex2100.htm Edgar Link pending
stemtech_ex3100.htm Edgar Link pending
stemtech_ex3200.htm Edgar Link pending
stemtech_i10k-123123.htm Edgar Link pending
stemtech_i10k-123123_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
gntw-20231231_lab.xml Edgar Link unprocessable
gntw-20231231_cal.xml Edgar Link unprocessable
gntw-20231231_pre.xml Edgar Link unprocessable
gntw-20231231_def.xml Edgar Link unprocessable